BioArctic AB (publ) (STO:BIOA.B)
289.40
+5.60 (1.97%)
Sep 24, 2025, 5:29 PM CET
BioArctic AB Revenue
BioArctic AB had revenue of 392.12M SEK in the quarter ending June 30, 2025, with 686.69% growth. This brings the company's revenue in the last twelve months to 1.86B, up 521.22% year-over-year. In the year 2024, BioArctic AB had annual revenue of 257.35M, down -58.22%.
Revenue (ttm)
1.86B
Revenue Growth
+521.22%
P/S Ratio
13.79
Revenue / Employee
15.63M
Employees
107
Market Cap
25.65B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 257.35M | -358.64M | -58.22% |
Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
Dec 31, 2020 | 65.21M | -217.74M | -76.95% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Swedish Orphan Biovitrum AB | 26.97B |
Sectra AB | 3.37B |
Getinge AB | 35.50B |
Camurus AB | 2.27B |
Medicover AB | 25.22B |
Asker Healthcare Group AB | 15.88B |
AddLife AB | 10.44B |
Bonesupport Holding AB | 1.06B |
BioArctic AB News
- 19 hours ago - Leqembi® approved for the treatment of early Alzheimer's disease in Australia - Benzinga
- 19 hours ago - Leqembi® approved for the treatment of early Alzheimer's disease in Australia - PRNewsWire
- 15 days ago - BioArctic: Gunilla Osswald awarded Uppsala University Alumnus of the year 2025 - PRNewsWire
- 21 days ago - BioArctic's founders intend to divest minor part of their shareholding - PRNewsWire
- 21 days ago - Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status - PRNewsWire
- 26 days ago - US FDA approves Leqembi® IQKLIK ™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease - PRNewsWire
- 27 days ago - BioArctic: Interim Report for the period April - June 2025 - PRNewsWire
- 4 weeks ago - BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties - PRNewsWire